Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Carol L. Ensinger"'
Autor:
Daniel L. Flynn, Michael Clare, Lance J. Stewart, Lawrence Chun, Karen M. Yates, Subha Vogeti, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Thiwanka Samarakoon, Thomas J. Rutkoski, William C. Patt, Tristan W. Patt, Wei-Ping Lu, Molly M. Hood, Carol L. Ensinger, Timothy M. Caldwell, R. John Booth, Yu Mi Ahn, Scott C. Wise, Benjamin A. Turner, Cynthia B. Leary, Michael D. Kaufman, Bryan D. Smith
Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but als
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a49f1af80ca00d7cc02eb5848964921
https://doi.org/10.1158/1535-7163.c.6536815.v1
https://doi.org/10.1158/1535-7163.c.6536815.v1
Autor:
Daniel L. Flynn, Michael Clare, Lance J. Stewart, Lawrence Chun, Karen M. Yates, Subha Vogeti, Lakshminarayana Vogeti, Hanumaiah Telikepalli, Thiwanka Samarakoon, Thomas J. Rutkoski, William C. Patt, Tristan W. Patt, Wei-Ping Lu, Molly M. Hood, Carol L. Ensinger, Timothy M. Caldwell, R. John Booth, Yu Mi Ahn, Scott C. Wise, Benjamin A. Turner, Cynthia B. Leary, Michael D. Kaufman, Bryan D. Smith
Supplementary Materials and Methods. Supplementary table 1: XRay crystallography parameters for DP-4157/MET complex. Supplementary table 2: Source and description of kinases. Supplementary table 3: Selectivity of profile of altiratinib inhibition fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b914b7bf5b2f07136ac99e3d894850d
https://doi.org/10.1158/1535-7163.22501534
https://doi.org/10.1158/1535-7163.22501534
Autor:
Molly M. Hood, Arin McKinley, Bryan D. Smith, Subha Vogeti, Gada Al-Ani, Wei Ping Lu, Ying Su, Ajia Town, Timothy M. Caldwell, Daniel L. Flynn, Lakshminarayana Vogeti, Michael Heinrich, Cynthia B. Leary, Patt William Chester, Lawrence Chun, Benjamin A. Turner, Oliver Rosen, Albiruni Ryan Abdul Razak, Karen M. Yates, Michael Kaufman, Carol L. Ensinger, Filip Janku, Rodrigo Ruiz-Soto, Hanumaiah Telikepalli, Yu Mi Ahn, Anu Gupta, Thomas J. Rutkoski, Stacie L. Bulfer, Scott C. Wise
Publikováno v:
Cancer cell. 35(5)
Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e2bf398b79e62d869adc0d45fdacd94
https://pubmed.ncbi.nlm.nih.gov/31201392
https://pubmed.ncbi.nlm.nih.gov/31201392
Autor:
R. John Booth, Bryan D. Smith, Daniel L. Flynn, Lance Stewart, Tristan W. Patt, Scott C. Wise, Timothy M. Caldwell, Benjamin A. Turner, Molly M. Hood, Thomas J. Rutkoski, Wei-Ping Lu, Yu Mi Ahn, Michael Kaufman, Hanumaiah Telikepalli, Michael Clare, Subha Vogeti, Patt William Chester, Thiwanka Bandara Samarakoon, Karen M. Yates, Lakshminarayana Vogeti, Cynthia B. Leary, Lawrence Chun, Carol L. Ensinger
Publikováno v:
Molecular Cancer Therapeutics. 14:2023-2034
Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer (1). Specifically, altiratinib inhibits not only mechanisms of tumor initiation and progression, but als
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0d9f008c69306495e16c6fdc2698a29
https://doi.org/10.1158/1535-7163.mct-14-1105
https://doi.org/10.1158/1535-7163.mct-14-1105
Autor:
Martin E. Kuehne, Anne E. Huot, Linda S. Borman, William G. Bornmann, Yong Qin, Feng Xu, Julia B. Cheung, Karen L. LeBoulluec, Fred Thomas Bizzarro, Christopher M. Exon, István E. Markó, Tshilundu Mulamba, Susan Bane, Carol L. Ensinger, Deborah A. Frasier
Publikováno v:
Org. Biomol. Chem.. 1:2120-2136
Sixty-two congeners of vinblastine (VLB), primarily with modifications of the piperidine ring in the carbomethoxycleavamine moiety of the binary alkaloid, were synthesized and evaluated for cytotoxicity against murine L1210 leukemia and RCC-2 rat col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6eea50f121986e8c50e22d7c9a68037
https://doi.org/10.1039/b209990j
https://doi.org/10.1039/b209990j
Autor:
Andrew T. Chiu, Santella Joseph B, Carol L. Ensinger, Duncia John, Pieter B.M.W.M. Timmermans, Mary K. VanAtten, Pancras C. Wong, Ruth R. Wexler, David J. Carini
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 4:2235-2240
We wish to report on a series of substituted methyl esters and amides of DMP 811, which bind to both the AT 1 and AT 2 receptor subtypes. Some of the esters bind well to both receptor subtypes in the subnanomolar range when the optimal acid isostere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::666e6a9bf381bd0478df7e0bc6173ed4
https://doi.org/10.1016/s0960-894x(00)80077-3
https://doi.org/10.1016/s0960-894x(00)80077-3
Autor:
Ruth R. Wexler, Pancras C. Wong, David J. Carini, Shiew-Mei Huang, Carol L. Ensinger, Bruce J. Aungst, James Russell Pruitt, Pieter B.M.W.M. Timmermans, Ardecky Rj
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 4:63-68
A novel series of 4-alkylimidazoles have been prepared. Two of these compounds, DMP 581, 4-ethyl-2-propyl- 1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidiazole-5-carboxaldehyde, and DMP 811, 4-ethyl-2-propyl-1-[[2′-(1H- tetrazol-5-yl)biphenyl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fe1d69ad474571b4151ccd629252c94
https://doi.org/10.1016/s0960-894x(01)81123-9
https://doi.org/10.1016/s0960-894x(01)81123-9
Autor:
Carol L. Ensinger, Bruce J. Aungst, Ruth R. Wexler, Pieter B.M.W.M. Timmermans, David J. Carini, Ardecky Rj, Shiew-Mei Huang, Pancras C. Wong, James Russell Pruitt
Publikováno v:
ChemInform. 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89b1d08809ab029204274b2a0be2c088
https://doi.org/10.1002/chin.199426158
https://doi.org/10.1002/chin.199426158
Autor:
Jan Abendroth, Lakshminarayana Vogeti, Daniel L. Flynn, Peter A. Petillo, Wei-Ping Lu, David F. Miller, Bryan D. Smith, Michael Kaufman, Lawrence Chun, Michael D. Feese, Carol L. Ensinger, Robin Clark, Molly M. Hood, Patt William Chester, Yu Mi Ahn, Hidong Kim, Lance Stewart, Michael Clare, Scott C. Wise, John Lord
Publikováno v:
Bioorganicmedicinal chemistry letters. 20(19)
Switch control pocket inhibitors of p38-alpha kinase are described. Durable type II inhibitors were designed which bind to arginines (Arg67 or Arg70) that function as key residues for mediating phospho-threonine 180 dependant conformational fluxing o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5351fd60e2e06e7e6d9391cf784455e3
https://pubmed.ncbi.nlm.nih.gov/20800479
https://pubmed.ncbi.nlm.nih.gov/20800479
Autor:
Daniel D. Sternbach, Carol L. Ensinger
Publikováno v:
The Journal of Organic Chemistry. 55:2725-2736
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf42709d24269a32c0a1b52189ebf368
https://doi.org/10.1021/jo00296a033
https://doi.org/10.1021/jo00296a033